

--33. The IBDV according to claim 32, wherein the mutant further comprises one or more stop codons in a part of the 5'-end of the VP5 gene that does not overlap with the large open reading frame (ORF). - -

--34. The IBDV mutant according to claim 33, wherein the mutant comprises a stop codon in each of the three ORFs. - -

DI
cont

--35. The IBDV mutant according to claim 32, wherein the mutation is in the genome of a virulent field virus. - -

--36. The IBDV mutant according to claim 32, wherein the mutation is in the genome of a vaccine strain. - -

--37. The IBDV mutant according to claim 36, wherein the vaccine strain is strain D78. - -

--38. The IBDV mutant according to claim 32, which expresses a chimeric VP2 protein comprising neutralizing epitopes of different antigenic IBDV types. - -

--39. A vaccine against an IBDV infection in animals, comprising an IBDV mutant according to claims 32 - 38, and a pharmaceutically acceptable carrier. - -
